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Leishmaniases are endemic in humans and animals in part of the European Union (EU) and its neigh-
boring countries. Leishmania species in this region 
are L. major, L. tropica, and the L. donovani complex 
species (including L. infantum and L. donovani sensu 
stricto). All cause cutaneous leishmaniasis (CL); vis-
ceral leishmaniasis (VL) is caused mainly by L. don-
ovani complex species. There is evidence that the risk 
for leishmaniases is increasing in some EU and neigh-
boring countries (1). We conducted a questionnaire 
survey to gather information on the epidemiologic 
situation, surveillance, prevention and control mea-
sures, and drivers of emergence of animal and human 
leishmaniases in this region during 2010–2020.
The Study
The survey included an animal leishmaniasis (AniL) 
questionnaire referring to L. infantum infections in do-
mestic or wildlife hosts and a human leishmaniases 
(HumL) questionnaire referring to infections by L. in-
fantum, L. major, L. tropica and L. donovani s.s. (Appen-
dix, https://wwwnc.cdc.gov/EID/article/27/6/21-
0239-App1.pdf). The target audience was the national 
focal points (national institutes or ministries) of the Eu-
ropean Centre for Disease Prevention and Control, the 
World Health Organization, the European Food Safety 
Authority, and the World Organisation for Animal 
Health in countries in which leishmaniases are endem-
ic or those with confi rmed or suspected presence of 
sand fl y vectors (2). These countries were Albania, Al-
geria, Armenia, Austria, Azerbaijan, Belgium, Bosnia 
and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, 
Egypt, France, Georgia, Germany, Greece, Hungary, 
Israel, Italy, Jordan, Kosovo, Lebanon, Libya, Liech-
tenstein, Luxembourg, Malta, Moldova, Montenegro, 
Morocco, North Macedonia, Palestine, Portugal, Ro-
mania, Serbia, Slovakia, Slovenia, Spain, Tunisia, Tur-
key, and Ukraine (Figure 1). The questionnaires were 
administered electronically using the EU survey tool 
and shared on September 11, 2020 (3). Twenty-seven 
countries (70%) replied to the AniL questionnaire and 
24 countries (60%) to the HumL questionnaires; 19 
countries (48%) replied to both (Table 1).
We reviewed the countries’ epidemiologic status 
with regards to autochthonous Leishmania spp. infec-
tions in animals and humans and clinical forms in 
humans. The mapping of the countries with autoch-
thonous transmission matches previous published 
information with few discrepancies. For instance, ac-
cording to the questionnaire, Bosnia and Herzegovi-
na and Hungary do not have autochthonous canine 
leishmaniasis cases, although such cases have been 
described (4,5). Human cases of leishmaniasis due to 
L. tropica were reported in Cyprus and Serbia and due 
to L. major in Georgia; however, none of the literature 
presents concurring evidence (Table 2).
Animal leishmaniases are notifi able in 17 countries 
and human leishmaniases in 20 countries (Table 1; Fig-
ure 2). In Palestine and Turkey, AniL is not notifi able 
despite a high prevalence among dogs (6,7). Similarly, 
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A questionnaire survey of animal and human health au-
thorities in Europe revealed that leishmaniases are not 
notifi able in all countries with autochthonous cases. Few 
countries implement surveillance and control targeting 
both animal and human infections. Leishmaniases are 
considered emergent diseases in most countries, and 
lack of resources is a challenge for control.
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in France, neither AniL nor HumL are notifiable al-
though the diseases are endemic in the south (8). Leish-
maniases surveillance is not mandatory at the EU level 
which constitutes a limitation for successful control.
Seven countries conduct AniL surveillance (Table 
1), indicative of its low priority among the animal health 
authorities. The target animal population for surveil-
lance included symptomatic and asymptomatic dogs 
in Armenia, Cyprus, Italy, Spain, and Ukraine; we also 
studied wildlife in leishmaniasis foci in Spain. Testing 
subclinically infected dogs indicated awareness of their 
role as reservoirs of the parasite (1). Similarly, wild lago-
morphs were the main reservoir of L. infantum in a HumL 
outbreak in Madrid in Spain (9). Surveillance of HumL 
is conducted in 19 countries, including all of those with 
autochthonous infections except Serbia (Table 1).
Antibody tests, including the immunofluores-
cence antibody test, ELISA, and the rapid immuno-
chromatography test, are the main surveillance di-
agnostic methods used, followed by PCR. Antibody 
tests play a fundamental role in disease surveillance 
because they are relatively cheap and easy to use (10). 
However, their sensitivity to detect subclinical infec-
tions is lower than that of PCR tests (10), and they do 
not discriminate naturally infected from vaccinated 
dogs (11). PCR tests are ideal for epidemiologic stud-
ies to estimate Leishmania spp. infection prevalence in 
healthy hosts, but their diagnostic validity depends 
on the sample used, the DNA sequence target, and 
the PCR protocol. Standardization of PCR tests in 
leishmaniasis diagnosis is needed (12).
Of the 7 countries that have ongoing AniL preven-
tion and control programs (Table 1), 5 use topical insecti-
cides for dogs, 5 are diagnosing and treating leishmani-
ases in dogs, and 2 use canine leishmaniosis vaccines. In 
all countries, infected dogs may be euthanized on wel-
fare grounds. Lack of funds and treatment costs were 
considered the most important AniL control challenges. 
Human leishmaniasis prevention and control activities 
are implemented in 12 countries (Table 1); for L. infan-
tum, actions focused on the use of insecticides on dogs, 
and for L. major, L. tropica, and L. donovani, the common 
activity was the use of peridomiciliary and intradomicil-
iary insecticides. Lack of funds and capacity constraints 
are considered the main challenges for HumL. 
Although zoonotic L. infantum strategies are cen-
tered on preventing and eliminating infections in 
dogs, the main parasite reservoir host, we found that 
insecticides and treatments are not fully effective and 
are expensive, and so provided to a relatively small 
proportion of dogs. Leishmaniasis control needs the 
One Health approach to account for the complexity 
of its transmission cycle involving humans, domestic 
animals, wildlife, and sand fly vectors (13).
Animal leishmaniases are considered emergent 
diseases in Cyprus and Jordan and in parts of Algeria, 
Figure 1. Geographic distribution of countries that responded to survey questionnaires about animal and human leishmaniases in 
Europe, 2020.
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Armenia, France, Georgia, Jordan, Montenegro, North 
Macedonia, Romania, Slovenia, Turkey, and Ukraine. 
The most important AniL emergence risk factor is the 
lack of control. Human leishmaniases are considered 
emerging diseases in Cyprus, Libya and Malta and in 
parts of Albania, Austria, Armenia, Azerbaijan, Geor-
gia, Israel, Italy, Montenegro, and Spain. The main risk 
factors for HumL emergence are vector expansion for 
L. infantum, and movement of infected persons between 
countries for L. major, L. tropica, and L. donovani.
In general, the perceived increasing risk for AniL 
and HumL was in line with the literature. In the EU 
and its neighborhood, the risks include movement of 
humans and dogs, increased number of immunosup-
pressed patients, climate warming, and other envi-
ronmental changes affecting vector and reservoir host 
distribution (1,14). Limitations associated with exist-
ing surveillance and control programs, along with 
the fact that leishmaniases are often regarded as a lo-
cal problem rather than a transnational problem, are 
deemed major obstacles to overcome to prevent leish-
maniases emergence in the EU and its neighborhood.
Conclusions
Leishmaniases are considered widespread, endemic, 
or emerging infections in the EU and its neighbor-
hood, yet are neglected and underreported because 
they are low priority at the country and EU level. Our 
study revealed a clear need to strengthen leishmania-
sis prevention and control programs in the EU and its 
neighborhood. We recommend analysis of leishmani-
asis incidence in the region for an objective assess-
ment of disease emergence, and also improvement of 
prevention and control programs based on a robust 
surveillance and following a One Health approach.
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Animal Human Animal Human Animal Human Animal Human 
Albania NR VL, CL  NR Yes  NR Yes  NR No 
Algeria Yes NR  Yes NR  Yes NR  Yes NR 
Armenia Yes VL  Yes Yes  Yes Yes  Yes Yes 
Austria Not known No  No No  No No  No No 
Azerbaijan NR VL, CL  NR Yes  NR Yes  NR Yes 
Belgium No No  No No  No Yes  No No 
Bosnia and 
Herzegovina 
No NR  Yes NR  No NR  No NR 
Bulgaria NR VL  NR Yes  NR Yes  NR Yes 
Croatia Yes VL, CL  Yes Yes  No Yes  No Not known 
Cyprus Yes VL, CL  Yes Yes  Yes Yes  No No 
Czechia Not known No  Yes Yes  No No  No No 
France Yes VL, CL  No No  No Yes  No No 
Georgia Yes VL  Yes Yes  No Yes  No Yes 
Germany Not known No  No No  No No  No No 
Greece Yes VL, CL  Yes Yes  No Yes  Yes Yes 
Hungary Not known NR  No NR  No NR  No NR 
Israel Yes VL, CL  Yes Yes  No Yes  No Yes 
Italy Yes VL, CL  Yes Yes  Yes Yes  Yes Yes 
Jordan Yes NR  Yes NR  No NR  No NR 
Libya NR VL, CL  NR Yes  NR Yes  NR Yes 
Luxemburg Not known NR  No NR  No NR  No NR 
Malta NR VL, CL  NR Yes  NR Yes  NR Yes 
Moldova No NR  Yes NR  No NR  No NR 
Montenegro No VL  Yes Yes  No Yes  Yes No 
North Macedonia Yes NR  Yes NR  Yes NR  Yes NR 
Palestine Yes NR  No NR  No NR  Yes NR 
Romania Yes No  No Yes  No No  No Not known 
Serbia Yes VL, CL  No No  No No  No Yes 
Slovenia Yes No  Yes Yes  No Yes  No No 
Spain Yes VL, CL  Regionally Yes  Yes Yes  No Yes 
Turkey Yes VL, CL  No Yes  No Yes  No Yes 
Ukraine Yes VL  Regionally Yes  Yes Yes  No No 
*Data source: questionnaires survey on animal and human leishmaniases to national focal points of the European Centre for Disease Prevention and 
Control, the World Health Organization, the European Food Safety Authority, and the World Organisation for Animal Health; survey conducted in 2020. 
CL, cutaneous leishmaniases; NR, no response; VL, visceral leishmaniases. 
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Figure 2. Geographic distribution of mandatory notification status for animal (A) and human (B) leishmaniases, 2020.
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Table 2. Declared status of endemicity of Leishmania spp.  
affecting humans, by country 
Country 
Leishmania species 
L. infantum L. major L. tropica L. donovani 
Albania Yes No No No 
Armenia Yes No No No 
Austria No No No No 
Azerbaijan Yes Yes Yes No 
Belgium No No No No 
Bulgaria Yes No No No 
Croatia Not known Not known Not known Not known 
Cyprus No No Yes Yes 
Czechia No No No No 
France Yes No No No 
Georgia Yes Yes No No 
Germany No No No No 
Greece Yes No No No 
Israel Yes Yes Yes No 
Italy Yes No No No 
Libya Yes Yes Yes Not known 
Malta Yes No No No 
Montenegro Yes Not known Not known No 
Romania No No No No 
Serbia Yes Not known Yes No 
Slovenia No No No No 
Spain Yes No No No 
Turkey Not known Not known Yes Not known 
Ukraine No No No No 
 
